15 January 2021
Innovation Pharmaceuticals announced that the US Food and Drug Administration (FDA) has granted the company fast track designation to investigate Brilacidin, a first-in-class Host Defence Protein mimetic with antiviral, antibacterial, and anti-inflammatory properties for the treatment of Covid-19.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The FDA Philippines has granted its first emergency use authorisation (EUA) to Pfizer and BioNTech’s Covid-19 vaccine, BNT162b2. An EUA is granted to a particular vaccine being developed in a situation when there is no adequate, available, and approved substitute for a preventative vaccine.
Relay Medical and Glow LifeTech announced successful results from their Phase II double-blind, placebo-controlled clinical trial for ArtemiC, a Covid-19 treatment that is based on the latter’s MyCell Technology. The treatment met its primary and secondary endpoints during the trial.
